NCCN and Proventys Collaborate to Enhance Quality and Efficiency in Cancer Care
NCCN and Proventys, a leader in advanced decision support technologies, have entered into an exclusive collaboration to introduce the Proventys CDS Oncology system, a first-of-its-kind Web platform that arms oncologists with expert recommendations and evidence facilitating the delivery of high-quality, individualized patient care. Through this collaboration, Proventys and NCCN are bringing together the recognized standard in oncology clinical guidelines and novel informatics technologies to help clinicians optimize treatment decisions for patients while improving practice efficiencies.
In today's complex healthcare environment, clinicians are facing increasing pressure to provide high-quality, cost-effective care consistent with evidence-based standards of medical practice. To address this demand, Proventys CDS Oncology was designed to automate the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) in a dynamic and structured fashion according to individual patient characteristics, and enable clinicians to access evidence-based recommendations efficiently within the clinical workflow. The Proventys system offers clinicians guidance on appropriate lab and imaging tests, provides information on cancer staging, and highlights the most relevant treatment regimens available for the patient based on NCCN Guidelines and other decision rules. As a key component of the collaboration, Proventys CDS Oncology will also feature real-time alerts of critical updates to the NCCN Guidelines reflecting the latest recommendations for cancer therapy.
“For clinicians to deliver the highest standard of care to cancer patients, it's imperative that they have easy, quick access to critical information that helps guide them in their treatment decisions,” said William T. McGivney, PhD, Chief Executive Officer of NCCN. “This collaboration with Proventys gives us the opportunity to equip clinicians with point-of-care access to the NCCN Guidelines and an ability to incorporate patient-specific factors through novel technology that assists clinical decision-making.”
“The collaboration between Proventys and NCCN represents the perfect blend of evidence-based medicine and information technology,” said Surya Singh, MD, Chief Medical Officer and Vice President of Clinical Development for Proventys. “Through our innovative informatics approach and NCCN's gold standard in oncology guidelines, we are, in essence, enhancing clinicians' ability to process complex data and treat their patients in a more personalized manner.”
Proventys CDS Oncology will be available for clinicians starting in the fourth quarter of 2010 and will also be offered through payer-sponsored quality programs. The system will initially include NCCN Guidelines for Breast, Colon, and Non–Small Cell Lung cancers as well as Hodgkin lymphoma.
NCCN Receives $4 Million in Oncology Research
NCCN has been awarded two individual $2 million grants from GlaxoSmithKline (GSK) to support clinical studies of ofatumumab (Arzerra, GlaxoSmithKline) in the treatment of hematologic malignancies and pazopanib (Votrient, GlaxoSmithKline) in the treatment of solid tumors.
The NCCN Oncology Research Program (ORP) facilitates all phases of clinical research by identifying clinical investigators and initiating trials at NCCN Member Institutions. The ORP draws on the expertise of investigators at 21 of the world's leading cancer centers and establishes collaborations with pharmaceutical and biotech companies in order to advance therapeutic options for patients with cancer. The ORP will use the grants from GSK to support investigator initiated clinical and correlative studies at its NCCN Member Institutions for both drugs. This research grant model has been very successful in moving science forward as evidenced by the many scientific articles published on ORP supported research.
